Cargando…

STAT3 mutation impacts biological and clinical features of T-LGL leukemia

STAT3 mutations have been described in 30-40% of T-large granular lymphocyte (T-LGL) leukemia patients, leading to STAT3 pathway activation. Considering the heterogeneity of the disease and the several immunophenotypes that LGL clone may express, the aim of this work was to evaluate whether STAT3 mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teramo, Antonella, Barilà, Gregorio, Calabretto, Giulia, Ercolin, Chiara, Lamy, Thierry, Moignet, Aline, Roussel, Mikael, Pastoret, Cédric, Leoncin, Matteo, Gattazzo, Cristina, Cabrelle, Anna, Boscaro, Elisa, Teolato, Sara, Pagnin, Elisa, Berno, Tamara, De March, Elena, Facco, Monica, Piazza, Francesco, Trentin, Livio, Semenzato, Gianpietro, Zambello, Renato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617471/ https://www.ncbi.nlm.nih.gov/pubmed/28977911 http://dx.doi.org/10.18632/oncotarget.18711

Ejemplares similares

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
por: Barilà, Gregorio, et al.
Publicado: (2018)

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder Really Two Distinct Diseases?
por: Zambello, Renato, et al.
Publicado: (2014)

Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?
por: Zambello, Renato, et al.
Publicado: (2014)

Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia
por: Mariotti, Barbara, et al.
Publicado: (2020)

LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don’t Make an Evidence
por: Calabretto, Giulia, et al.
Publicado: (2022)

Toward a Better Classification System for NK-LGL Disorders
por: Drillet, Gaëlle, et al.
Publicado: (2022)

Cyclophosphamide as a first-line therapy in LGL leukemia
por: Moignet, A, et al.
Publicado: (2014)

HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen
por: Frezzato, Federica, et al.
Publicado: (2012)

Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia
por: Teramo, Antonella, et al.
Publicado: (2020)

Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options
por: Calabretto, Giulia, et al.
Publicado: (2021)

Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?
por: Giussani, Edoardo, et al.
Publicado: (2021)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells
por: Gasparini, Vanessa Rebecca, et al.
Publicado: (2020)

Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
por: Barilà, Gregorio, et al.
Publicado: (2020)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis
por: Agostini, Carlo, et al.
Publicado: (2005)

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival
por: Trimarco, Valentina, et al.
Publicado: (2015)

Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research
por: Manni, Sabrina, et al.
Publicado: (2020)

Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation
por: Teramo, Antonella, et al.
Publicado: (2022)

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma
por: Carrino, Marilena, et al.
Publicado: (2019)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
por: Bhattacharya, Dipabarna, et al.
Publicado: (2022)

Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience
por: Calabretto, Giulia, et al.
Publicado: (2022)

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
por: Barilà, Gregorio, et al.
Publicado: (2023)

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
por: Piazza, Francesco, et al.
Publicado: (2010)

CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
por: Fregnani, Anna, et al.
Publicado: (2022)

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma
por: Canovas Nunes, Sara, et al.
Publicado: (2018)

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
por: Manni, Sabrina, et al.
Publicado: (2013)

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
por: Bacci, Christian, et al.
Publicado: (2021)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis
por: Facco, M., et al.
Publicado: (2015)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
por: Ceccato, Jessica, et al.
Publicado: (2022)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI
por: Zambello, Renato, et al.
Publicado: (2018)

Inhibition of glioblastoma malignancy by Lgl1
por: Gont, Alexander, et al.
Publicado: (2014)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia
por: Martini, Veronica, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lh8dajph8ntusv9a10qi7u5m0j